Inhaled cromolyn sodium for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an inhaled medication called cromolyn sodium for people with stage 3 lung cancer. It may help by targeting tumors in the lung directly through breathing in the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3 lung cancer (locally advanced) or a type called lung adenocarcinoma.
- You are 18 years or older.
- A previous scan showed a tumor in your lung.
- You haven't taken any other experimental drug or device within the last 4 weeks (6 weeks for certain drugs).
- You don't have fluid around your heart (known pericardial effusion).
- You are not allergic to cromolyn sodium.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new approach for advanced non-small cell lung cancer that cannot be surgically removed. It combines a focused, high-dose radiation treatment to the tumor core followed by standard chemotherapy and radiation together. This may help fight the cancer more effectively.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.